Acrivon Therapeutics, Inc. · NASDAQ:ACRV
Acrivon Therapeutics — Technical Presentation (November 2026)
14 slides from Acrivon Therapeutics's technical presentation, Nov 20, 2026
Slide 1: Safety, dose optimization, and early Phase 1/2 clinical results for ACR-2316
Safety, dose optimization, and early Phase 1/2 clinical results in AP3-predicted tumors for ACR-2316, a first-in-class WEE1/PKMYT1 inhibitor Timothy A. Yap1, Mohamad A. Salkeni2, Neel Gandhi3, Gerald Falchook4, David Sommerhalder5, Benedito A. Carneiro6, Judy Wang7, Monica Mita8, Kamlesh K. Sankhala
Slide 2: Disclosures
Disclosures Timothy A. Yap Employee of: University of Texas MD Anderson Cancer Center, where I am Vice President, Head of Clinical Development in the Therapeutics Discovery Division, which has a commercial interest in IACS-6274 and other inhibitors (IACS30380/ART0380 was licensed to Artios) Consulta
Slide 3: WEE1 and PKMYT1 - critical cell cycle checkpoints in human cancer
WEE1 and PKMYT1 - critical cell cycle checkpoints in human cancer Defective DNA repair is highly prevalent in cancers, creating a dependency on S- and G2/M checkpoint proteins, such as WEE1 and PKMYT1 Acrivon Predictive Precision Proteomics (AP3) measures the global cellular effects of a drug on the
Slide 4: ACR-2316: uniquely designed by AP3 for superior therapeutic index
ACR-2316: uniquely designed by AP3 for superior therapeutic index over WEE1 and PKMYT1 inhibitors Drug Designed by AP3 to suppress resistance mechanisms A differentiated, potentially first-in -class WEE1/PKMYT1 inhibitor Designed for high selectivity for WEE1 and PKMYT1 to overcome resistance and to
Slide 5: Study design and objectives
Oral, once daily, 3-week cycles, until progression or unacceptable toxicity. Tumor assessments per RECIST v1.1 every 6 weeks. Study design and objectives Cohort A 3d on/4d off Cohort B 2d on/5d off 120 mg 160 mg AP3-identified, molecularly defined tumor types Dose Escalation – 2 intermittent QD oral
Slide 6: ACR-2316 Patient demographics and baseline characteristics
ACR-2316 Patient demographics and baseline characteristics Subject Demographics N = 33 Median age, years (range) 63 (35–77) Sex, n (%) Female 20 (60.6) Male 13 (39.4) Race, n (%) White 26 (78.8) Black/African American 3 (9.1) Asian 1 (3.0) Native Hawaiian/Pacific Islander 1 (3.0) Other/Unknown/Not R
Slide 7: ACR-2316 Safety: treatment-related adverse events
ACR-2316 Safety: treatment-related adverse events Grade ≥3 TRAEs (≥5% overall) – Dose-escalation population, Cohort A 120 mg and 160 mg Grade ≥3 TRAEs Overall N = 33 (Cohorts A and B) Cohort A 120 mg (n = 4) Cohort A 160 mg (n = 4) Grade 3 n (%) Grade 4 n (%) Grade ≥3 n (%) Grade 3 n (%) Grade 4 n (
Slide 8: Tolerability of ACR-2316
TRAE = treatment-related adverse event; DLT = dose-limiting toxicity. Dose interruption includes delays and holds. Dose-escalation population (N = 33), Cohort A 120 mg and 160 mg Tolerability of ACR-2316 Tolerability endpoints n (%) Overall N = 33 120 mg n = 4 160 mg n = 4 Any TRAE 26 (78.8) 3 (75.0
Slide 9: Favorable dose-proportional PK of ACR-2316 with minimal accumulation
Favorable dose-proportional PK of ACR-2316 with minimal accumulation T1/2 ~ 12h
Slide 10: Drug target engagement of ACR-2316 in patient PBMCs
Drug target engagement of ACR-2316 in patient PBMCs from 1st dose level (AP3 MS assay) CDK1 CDK2 (QxxxxxxS/TPxxKxxx) CDK5 (xTxxxxxS/TPxxxxEx) PLK1 (xxxxLDxS/TxxExxxx) AKT1 (xxRxRxxS/TxSxxxxx) AKT2 (xxxxRxxS/TxSxxxxx) Drug-regulated P-sites (paired t-test : p-value < 0.05) (xxxxxxxS/TPxK/RxxSx) N=321
Slide 11: Promising clinical activity of ACR-2316 observed at doses ≥120 mg
Promising clinical activity of ACR-2316 observed at doses ≥120 mg Weeks on Treatment (N =25) Best Tumor Shrinkage Best % Change from Baseline % Change in Target Lesions from Baseline Target Lesion Change Over Time Subjects dosed at ≥120 mg with ≥1 on treatment scan (N =25) Off Treatment On Study SqN
Slide 12: Durable clinical activity of ACR-2316 in heavily pretreated lung cancer patients
Durable clinical activity of ACR-2316 in heavily pretreated lung cancer patients % Change in Target Lesions (On-Treatment Scans) Duration of Last Prior Therapy and Time on ACR-2316 by Patient 0 5 10 15 20 25 30 35 40 45 50 55 60 65 70 adNSCLC-01 adNSCLC-02 adNSCLC-03 sqNSCLC-01 sqNSCLC-02 SCLC-01 SC
Slide 13: ACR-2316: Conclusions
ACR-2316: Conclusions Highly differentiated, potentially first-in-class oral WEE1/PKMYT1 inhibitor Rationally designed with the AP3 platform for superior single-agent activity through dual Wee1/PKMYT1 inhibition and activation of not only CDK1 and CDK2, but also PLK1 Favorable safety profile Predomi
Slide 14: ACR-2316: Acknowledgments
ACR-2316: Acknowledgments To our patients and their families Our deepest gratitude goes to every patient who has taken part, and continues to take part, in this study, and to the families and caregivers who stand beside them. Your trust, courage and generosity are the foundation of everything we are
Acrivon Therapeutics — Technical Presentation (November 2026) on 6ix